Shukui Qin Selected Research

Hand-Foot Syndrome

2/2022	Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
1/2021	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
1/2021	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
1/2019	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
11/2013	Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shukui Qin Research Topics

Disease

60	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 01/2009
41	Neoplasms (Cancer) 06/2022 - 05/2009
18	Hypertension (High Blood Pressure) 02/2022 - 04/2012
17	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2021 - 05/2009
15	Stomach Neoplasms (Stomach Cancer) 01/2021 - 12/2011
14	Disease Progression 12/2021 - 07/2011
11	Colorectal Neoplasms (Colorectal Cancer) 07/2021 - 06/2015
8	Exanthema (Rash) 01/2019 - 07/2010
7	Diarrhea 02/2022 - 04/2012
7	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2014
7	Renal Cell Carcinoma (Grawitz Tumor) 03/2020 - 09/2012
6	Proteinuria 02/2022 - 01/2015
6	Carcinoma (Carcinomatosis) 12/2021 - 01/2012
6	Neutropenia 05/2021 - 07/2010
6	Fatigue 01/2021 - 01/2009
5	Hand-Foot Syndrome 02/2022 - 11/2013
5	Adenocarcinoma 12/2021 - 12/2011
5	Thrombocytopenia (Thrombopenia) 03/2020 - 11/2013
3	Hepatitis B 12/2021 - 11/2013
3	Fibrosis (Cirrhosis) 12/2021 - 02/2015
3	Breast Neoplasms (Breast Cancer) 01/2021 - 06/2017
3	Liver Neoplasms (Liver Cancer) 01/2021 - 02/2002
3	Anemia 01/2019 - 09/2012
3	Lung Neoplasms (Lung Cancer) 06/2018 - 08/2012
2	Thyroid Neoplasms (Thyroid Cancer) 02/2022 - 01/2014
2	Hepatic Encephalopathy 01/2022 - 11/2020
2	Hepatitis C 12/2021 - 11/2013
2	Starvation 12/2021 - 01/2014
2	Febrile Neutropenia 12/2021 - 07/2010
2	Infections 03/2021 - 01/2016
2	Carcinogenesis 01/2021 - 04/2017
2	Pain (Aches) 01/2021 - 01/2021
2	Hypophosphatemia 08/2020 - 09/2012
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2019 - 04/2016
2	Retinoblastoma (Glioblastoma, Retinal) 03/2019 - 01/2017
2	Dyspnea (Shortness of Breath) 01/2018 - 03/2013
2	Colonic Neoplasms (Colon Cancer) 06/2017 - 02/2010

Drug/Important Bio-Agent (IBA)

28	Sorafenib (BAY 43-9006)FDA Link 04/2022 - 01/2009
14	apatinibIBA 02/2022 - 09/2013
14	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2022 - 10/2013
12	Pharmaceutical PreparationsIBA 08/2020 - 01/2009
11	Tyrosine Kinase InhibitorsIBA 01/2020 - 07/2011
9	Fluorouracil (Carac)FDA LinkGeneric 12/2021 - 10/2013
8	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2017
8	Bevacizumab (Avastin)FDA Link 04/2022 - 01/2015
7	atezolizumabIBA 04/2022 - 01/2020
7	Leucovorin (Folinic Acid)FDA Link 12/2021 - 10/2013
7	PlatinumIBA 12/2021 - 05/2009
7	camrelizumabIBA 12/2021 - 01/2020
6	Immune Checkpoint InhibitorsIBA 04/2021 - 01/2019
6	Gemcitabine FDA Link 04/2020 - 01/2011
6	Cisplatin (Platino)FDA LinkGeneric 05/2019 - 09/2014
6	Proteins (Proteins, Gene)FDA Link 03/2019 - 01/2014
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 07/2012
5	Alanine Transaminase (SGPT)IBA 01/2022 - 07/2012
5	HMPL-013IBA 05/2021 - 01/2018
5	Trastuzumab (Herceptin)FDA Link 01/2021 - 02/2016
5	lenvatinibIBA 01/2021 - 01/2018
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2013
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021 - 03/2013
4	Capecitabine (Xeloda)FDA Link 01/2021 - 01/2015
4	Monoclonal AntibodiesIBA 01/2021 - 01/2017
4	Sunitinib (Sutent)FDA Link 03/2020 - 12/2011
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019 - 02/2015
4	EndostatinsIBA 06/2018 - 08/2012
4	Axitinib (AG 013736)IBA 05/2018 - 01/2014
4	endostar proteinIBA 06/2015 - 08/2012
3	Angiogenesis InhibitorsIBA 01/2021 - 08/2012
3	regorafenibIBA 08/2020 - 06/2015
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2019 - 07/2012
3	Phosphotransferases (Kinase)IBA 01/2019 - 01/2012
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2019 - 05/2016
3	human ERBB2 proteinIBA 01/2019 - 02/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2019 - 04/2012
2	pembrolizumabIBA 01/2022 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 01/2018
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 12/2017
2	ginsenoside Rg3IBA 12/2021 - 06/2019
2	Long Noncoding RNAIBA 12/2021 - 01/2021
2	Antineoplastic Agents (Antineoplastics)IBA 12/2021 - 02/2010
2	tepotinibIBA 01/2021 - 01/2018
2	LigandsIBA 01/2021 - 01/2020
2	Lapatinib (GW572016)FDA Link 01/2021 - 06/2017
2	surufatinibIBA 11/2020 - 11/2020
2	anlotinibIBA 01/2020 - 01/2019
2	Cyclin D1IBA 06/2019 - 01/2017
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 06/2019 - 03/2019
2	Etoposide (VP 16)FDA LinkGeneric 05/2019 - 04/2016
2	capmatinibIBA 01/2019 - 01/2018
2	Tyrosine (L-Tyrosine)FDA Link 01/2019 - 01/2012
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2019 - 08/2018
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2018 - 10/2013
2	MicroRNAs (MicroRNA)IBA 04/2017 - 01/2016
2	BilirubinIBA 01/2017 - 07/2012
2	Gefitinib (Iressa)FDA Link 01/2017 - 09/2013

Therapy/Procedure

38	Drug Therapy (Chemotherapy) 12/2021 - 05/2009
37	Therapeutics 04/2022 - 01/2009
2	Hepatectomy 03/2021 - 07/2012
2	Immunotherapy 01/2019 - 12/2011
2	Radiotherapy 01/2017 - 06/2015